As of 2016, migraine has a global prevalence of 14.1%, but the prevalence and severity of this disease is often underestimated. Furthermore, stigma still surrounds migraine at work and in society in general, as it is viewed as a ‘common problem’, hindering patients from receiving the proper treatment.

Healthcare professionals are urged to recommend lifestyle modifications in addition to pharmacological intervention in managing patients with dyslipidaemia. The role of plant stanols in low-density lipoprotein cholesterol (LDL-C) lowering has been demonstrated in various studies across Western and Asian populations.

Dengue fever is a prevalent, potentially fatal but preventable infection. This mosquito-borne disease is a major cause of morbidity and mortality in Singapore. This course will discuss the epidemiology and burden of dengue disease.

Dengue viruses can cause either symptomatic infections or asymptomatic seroconversion. Symptomatic infection is systemic and dynamic, with clinical, haematological and serological profiles that change from day to day. A knowledge of the changes during each phase of dengue disease will enable a rational approach in its management. This course will discuss the manifestations and management of dengue disease.

Dengue is the most rapidly spreading mosquito-borne viral disease in the world. This febrile illness is a leading cause of illness and death in the tropics and subtropics. Vector control in most endemic countries is frequently insufficient or ineffective due to inadequate infrastructure, delayed initiation, short-term interventions, and insecticide resistance. This course will discuss the prevention of dengue disease, including clinical evidence on the dengue vaccine.

In the EMPA-REG OUTCOME (Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients) trial, empagliflozin demonstrated a reduction in cardiovascular events in patients with type 2 diabetes (T2D) and pre-existing cardiovascular disease. This online course covers the evidence base on the use of the sodium-glucose cotransporter 2 (SGLT2) inhibitor, empagliflozin, in the management of T2D patients with heart failure and chronic kidney disease.

The course highlights the current trends in the treatment of melanoma, focusing on personalised medicine and the evidence base for combination treatment with BRAFi + MEK inhibitor in melanoma and existing clinical trials. The course also discusses adverse event management and introduces the clinical trials that examined adjuvant therapy with checkpoint inhibitors or targeted therapy in melanoma patients with high risk of recurrence.